Thalamus size identified as an early indicator of future memory struggles

A single brain scan taking a static snapshot of brain tissue volume can forecast future cognitive decline better than tracking brain shrinkage over time. This approach offers a practical way to identify people at risk for dementia by assessing their brain’s built-in structural reserve. The research was published in Cortex.

As people grow older, they can accumulate physical damage inside their brains caused by diseases like Alzheimer’s. Yet, individuals with similar amounts of this microscopic damage often experience vastly different levels of memory loss. Some older adults maintain relatively sharp thinking skills despite harboring the physiological hallmarks of dementia.

Researchers use a concept called brain reserve to explain this variation. Brain reserve acts like a structural buffer or an emergency backup system for the mind. A person with high reserve can withstand more disease pathology before they start losing their ability to remember daily events or solve basic problems.

To measure this brain reserve, medical professionals face an ongoing debate. Some researchers prefer to look at the brain’s total structural volume at a single moment in time. Others argue that tracking the dynamic rate of brain tissue loss across several years provides a better picture of disease progression.

Nicola Sambuco, a neuroscientist at the University of Bari Aldo Moro in Italy, led a study to investigate this divide. Sambuco and his colleagues wanted to see if the brain’s starting physical hardware is a better predictor of future cognitive health than the speed at which that hardware breaks down. Resolving this question could change how doctors identify patients at the highest risk for developing dementia.

The research team focused heavily on individuals with mild cognitive impairment. This condition represents a transitional stage between normal age-related memory changes and full clinical dementia. People with mild cognitive impairment have a highly variable future, as some rapidly lose their memory while others never progress to a more severe state.

The researchers analyzed medical records from seventy-five participants enrolled in the Alzheimer’s Disease Neuroimaging Initiative. These individuals spanned a wide range of cognitive health. The group included twenty-six healthy older adults, forty-one people with mild cognitive impairment, and eight individuals already diagnosed with dementia.

To ensure high-quality data, the study authors only included participants who had undergone very specific, high-resolution brain scans. The participants also needed a complete battery of memory and thinking tests on file. These tests evaluated multiple mental domains, including complex attention, language skills, memory recall, and executive function, which involves planning and mental flexibility.

About twenty-one months after their initial tests, the participants returned for follow-up brain scans and a second round of cognitive assessments. The research team calculated how much each patient’s test scores changed over this period. They also measured how much each patient’s brain structure shrank between the first and second visits.

The researchers used specialized software to strip away the skull in the digital images and precisely segment the brain tissue. This allowed them to calculate an exact three-dimensional volume for each specific anatomical region. Using mathematical tools, they harmonized the images from different types of scanning machines to ensure all measurements were directly comparable.

The team zeroed in on three specific brain regions known to be affected by aging and dementia. They measured the hippocampus, a seahorse-shaped structure responsible for memory formation. They looked at the thalamus, a sensory relay station sitting deep in the center of the brain. They also examined the lateral ventricles, which are cavities filled with fluid that expand as surrounding brain tissue dies.

The initial brain scans yielded much better predictions of future memory problems than the short-term changes in brain size. The speed at which the brain shrank over the two-year period did not reliably predict how a patient’s test scores would change. Instead, the total amount of brain volume a patient had at their very first visit dictated their future mental sharpness.

When patients had a smaller hippocampus and a smaller thalamus at their first visit, they experienced worse memory and thinking outcomes two years later. On the flip side, people with larger lateral ventricles at the start of the study faced a faster decline in general thinking skills and complex attention. These baseline measurements provided a robust snapshot of each person’s accumulated structural health.

The results point to the thalamus as a central hub for maintaining mental capacity. Medical professionals traditionally focus on the hippocampus when studying memory loss in older adults. This study shows the anterior and medial sections of the thalamus play an equally vital role in preserving both memory and executive function.

When the anterior and medial parts of the thalamus were smaller, patients struggled to properly encode and consolidate new memories. They performed worse on tasks requiring them to recall lists of words or recognize objects they had seen previously. This suggests that the brain’s reserve relies on an extended network of connected regions, rather than just the hippocampus alone.

These static brain measurements also accurately predicted which patients with mild cognitive impairment would eventually develop clinical dementia. Over the course of the study, twenty patients transitioned from mild impairment to full dementia. The researchers built a statistical model using just the initial brain snapshot to see if they could anticipate this outcome.

The mathematical model successfully flagged the patients whose condition worsened, distinguishing them from the twenty-one patients whose cognitive abilities remained relatively stable. It achieved a high accuracy rate, demonstrating that a single baseline scan holds immense practical value. Doctors could plug initial brain volumes into a similar model to gauge an individual’s future disease risk.

The research team also looked at genetic risk factors within the group of patients with mild cognitive impairment. They examined a specific gene variant that heavily increases the risk of Alzheimer’s disease. This genetic marker was highly present in both the patients who progressed to dementia and those who did not.

Because the genetic risk was shared equally across these groups, genetics alone could not explain why only some patients declined. Instead, the total volume of brain tissue available at the start of the study appeared to determine who deteriorated. The physical capacity of the brain provided a shield against the onset of severe memory symptoms.

While the study offers practical insights, the researchers noted a few limitations. The reliance on complete, high-resolution datasets restricted the total number of participants to seventy-five. This small sample size might have made it difficult to detect subtle links between dynamic brain shrinkage rates and cognitive decline.

The average tracking period of twenty-one months was also relatively short in the context of neurodegenerative diseases. While initial brain volumes were the best predictors in this short timeframe, tracking the rate of brain shrinkage over a decade might yield different results. Short-term observations tend to favor baseline measurements because dynamic tissue loss happens slowly.

Additionally, the research team lacked the biological data needed to confirm the presence of amyloid plaques in most participants. Amyloid plaques are microscopic protein buildups that serve as a hallmark of Alzheimer’s disease. Without this specific data, the researchers could not definitively say whether all the patients experiencing memory loss suffered from Alzheimer’s pathology or from a different underlying condition.

Future research will need to test the statistical prediction model on entirely independent groups of patients. Validating the model outside of the original study population helps confirm that the tool is ready for real-world medical settings. Expanding the investigation to include specific protein biomarkers will also help separate patients based on their precise disease types.

The study, “Baseline brain volumes predict cognitive decline more robustly than atrophy rates: Evidence for brain reserve,” was authored by Nicola Sambuco, Giorgia F. Scaramuzzi, Daphne Gasparre, Ester Cornacchia, Aurora Bonvino, Linda A. Antonucci, Giulio Pergola, and Paolo Taurisano.